An Adaptive Dose Finding Design (DOSEFIND) Using A Nonlinear Dose Response Model
First-in-man (FIM) Phase I clinical trials are part of the critical path in the development of a new compound entity (NCE). Since FIM clinical trials are the first time that an NCE is dosed in human subjects, the designs used in these trials are unique and geared toward patient safety. We develop a...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
VCU Scholars Compass
2007
|
| Subjects: | |
| Online Access: | http://scholarscompass.vcu.edu/etd/695 http://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1694&context=etd |